Janux Therapeutics (JANX) Stock Forecast & Price Target

$46.69

+0.07 (+0.15%)

(As of 03:03 PM ET)

Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Janux Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for JANX.

Consensus Price Target

$66.13
44.63% Upside

According to the 9 analysts' twelve-month price targets for Janux Therapeutics, the average price target is $66.13. The highest price target for JANX is $100.00, while the lowest price target for JANX is $42.00. The average price target represents a forecasted upside of 44.63% from the current price of $46.69.

Get the Latest News and Ratings for JANX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors.

JANX Analyst Ratings Over Time

Type	Current Forecast 9/28/23 to 9/27/24	1 Month Ago 8/29/23 to 8/28/24	3 Months Ago 6/30/23 to 6/29/24	1 Year Ago 9/28/22 to 9/28/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$66.13	$65.57	$66.29	$28.33
Forecasted Upside	44.63% Upside	48.32% Upside	58.24% Upside	189.86% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

The Bible Says it Clear As Day (Ad)

It came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This parable teaches us that it’s our duty, and our challenge, to grow our money … to invest it and put it to good use … rather than keeping it stuffed away in a savings account, or wasting it in some frivolous way. In this video, Wall Street expert Charles Mizrahi shows me a secret that has helped me … and tons of other hardworking Americans … learn to invest just like the pros on Wall

Click here to join me in the “Miracle on Main Street.”

JANX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JANX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Janux Therapeutics Stock vs. The Competition

Type	Janux Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	44.63% Upside	798.81% Upside	6.11% Upside
News Sentiment Rating	Positive News See Recent JANX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$100.00 ➝ $100.00	+101.61%
9/6/2024	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Buy	$70.00	+60.15%
8/19/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$63.00 ➝ $63.00	+52.47%
8/9/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$47.00 ➝ $42.00	+17.12%
8/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$74.00 ➝ $74.00	+108.27%
4/16/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+34.98%
Get the Latest News and Ratings for JANX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
3/21/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$62.00	+58.45%
3/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$24.00 ➝ $48.00	+22.79%
2/27/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:24 PM ET.

JANX Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Janux Therapeutics is $66.13, with a high forecast of $100.00 and a low forecast of $42.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JANX shares.
: According to analysts, Janux Therapeutics's stock has a predicted upside of 41.63% based on their 12-month stock forecasts.
: Janux Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Scotiabank, Stifel Nicolaus, and Wedbush in the past 90 days.
: Analysts like Janux Therapeutics more than other "medical" companies. The consensus rating score for Janux Therapeutics is 2.89 while the average consensus rating score for "medical" companies is 2.78. Learn more on how JANX compares to other companies.